CIMA Labs
This article was originally published in The Tan Sheet
Executive Summary
Royalties and manufacturing revenues from Wyeth's Alavert expected to be major contributor to sales growth for fast-dissolve technology firm in 2003. Loratadine product "should end up this year [contributing] about 10% of our total revenues," President & CEO John Seibert, PhD, said during Feb. 20 analysts call. He noted Wyeth is "looking at this as the largest OTC product introduction in their history, and these are the people that brought you Advil." CIMA signed an exclusive supply agreement with Wyeth last June; Alavert employs CIMA's DuraSolv technology (1"The Tan Sheet" July 22, 2002, In Brief). Seibert estimated OTCs using CIMA technology account for 25% to 30% of the firm's revenues. CIMA's Q4 sales grew 68.5% to $15.5 mil., while annual sales rose 45.6% to $46.6 mil...